IndiaTicker
Ask IndiaTicker
IndiaTicker account

Keep your research close.

Save companies, build watchlists and return to your work from any device.

New to IndiaTicker? We create your account automatically. No password.

By continuing, you agree to the Terms and Privacy Policy.

Use an existing password
Company dossier

Aurobindo Pharma

NSE:AUROPHARMA · ISIN INE406A01037

Close
Unavailable
Date unavailable
Daily change
N/A
Exchange close
Evidence state
Building
0/0 checks
Aurobindo Pharma

Financials

Revenue₹8,853.3 Cr+2.4% vs prior period
Profit before tax₹1,293 Cr-3.4% vs prior period
Profit after tax₹920.8 Cr+1.2% vs prior period
EPS₹15.86+1.2% vs prior period
Structured filings

Reported financial periods

Exchange XBRL
MetricQuarter · FY26 · 31 Mar 26FY26 · 31 Dec 25Half year · FY26 · 30 Sept 25Quarter · FY26 · 30 Jun 25FY25 · 31 Mar 25Quarter · 31 Dec 24
Revenue₹8,853.3 Cr₹8,645.9 Cr₹8,285.7 CrN/AN/A₹7,978.5 Cr
Profit before tax₹1,293 Cr₹1,338.2 Cr₹1,274.3 CrN/AN/A₹1,198.3 Cr
Profit after tax₹920.8 Cr₹909.8 Cr₹848.1 CrN/AN/A₹845.6 Cr
Finance cost₹98.2 Cr₹92.8 Cr₹95.2 CrN/AN/A₹118.5 Cr
ImpairmentN/AN/AN/AN/AN/AN/A
EPS₹15.86₹15.67₹14.61N/AN/A₹14.56
₹ crore except EPS · consolidated · preferred filing per periodBSE XBRL
Accounting lens

What deserves analyst attention

Research framework
Period comparability

Confirm quarterly, year-to-date and annual periods before calculating growth. The table preserves the exchange period labels.

Standalone vs consolidated

Treat scope changes as breaks in comparability and open the linked XBRL before relying on a trend.

Company-specific concepts

Sector metrics and accounting choices require additional facts beyond this common cross-company layer.